Protagonist Therapeutics Inc (PTGX)
NASDAQ:PTGX
Want to see PTGX full AI Analyst Report?
PTGX Stock Chart & Stats
$105.98
-$0.87(-2.26%)
At close: 4:00 PM EST
$105.98
-$0.87(-2.26%)
Day’s Range― - ―
52-Week Range$49.38 - $111.78
Previous CloseN/A
Volume120.35K
Average Volume (3M)580.41K
Market Cap
$7.06B
Enterprise Value$6.22B
Total Cash (Recent Filing)$547.79M
Total Debt (Recent Filing)$9.78M
Price to Earnings (P/E)―
Beta0.02
Next Earnings
Jul 30, 2026EPS Estimate
2.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.80
Shares Outstanding64,311,370
10 Day Avg. Volume702,606
30 Day Avg. Volume580,415
Financial Highlights & Ratios
PEG Ratio0.29
Price to Book (P/B)9.03
Price to Sales (P/S)120.66
P/FCF Ratio99.01
Enterprise Value/Market Cap0.88
Enterprise Value/Revenue83.97
Enterprise Value/Gross Profit84.43
Enterprise Value/Ebitda-54.59
Forecast
1Y Price Target
$117.00Price Target Upside10.40% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)4.03
Revenue Forecast (FY)$503.79M
Bulls Say, Bears Say
Bulls Say
Strong Balance SheetA conservative capital structure with minimal debt and substantial equity provides durable funding flexibility to support multi-year clinical programs. It reduces refinancing risk, enables internal R&D funding, and preserves strategic optionality for partnerships or acquisitions over the medium term.
High Gross Margin & Revenue AccelerationExceptionally high gross margins and strong recent revenue growth suggest scalable, low-cost delivery consistent with licensing/partner revenue. This structural profitability potential supports reinvestment into the pipeline and strengthens the economics of future partnered or self-commercialized products if development succeeds.
Partnership-driven Business ModelA collaboration/licensing model shifts commercialization burden to partners and provides milestone and reimbursed R&D funding. For a clinical-stage peptide developer, partner alignment derisks late-stage costs, supplies non-dilutive funding, and offers clearer commercialization routes if candidates progress.
Bears Say
Sustained Negative Cash FlowMaterial negative operating and free cash flow over the trailing twelve months erodes cash reserves and heightens reliance on external financing or partner payments. Persistent burn constrains strategic flexibility and raises dilution risk if clinical timelines extend or additional studies are required.
Deeply Negative Profitability & Volatile ReturnsExtreme negative margins and negative ROE signal the company is currently unable to convert revenue into sustainable profits and has shown earnings volatility. This reduces earnings quality and long-term return prospects, complicating reinvestment planning and increasing financial execution risk.
Dependence On Partners And Milestone FundingHeavy reliance on partner deals and milestone-triggered payments makes funding contingent on external agreements and trial outcomes. If partnerships stall or milestones are missed, the company may face abrupt funding gaps, forcing dilutive financing, program delays, or curtailment of development activities.
Protagonist Therapeutics News
PTGX FAQ
What was Protagonist Therapeutics Inc’s price range in the past 12 months?
Protagonist Therapeutics Inc lowest stock price was $49.38 and its highest was $111.78 in the past 12 months.
What is Protagonist Therapeutics Inc’s market cap?
Protagonist Therapeutics Inc’s market cap is $7.06B.
When is Protagonist Therapeutics Inc’s upcoming earnings report date?
Protagonist Therapeutics Inc’s upcoming earnings report date is Jul 30, 2026 which is in 47 days.
How were Protagonist Therapeutics Inc’s earnings last quarter?
Protagonist Therapeutics Inc released its earnings results on May 05, 2026. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of -$0.5 by $0.55.
Is Protagonist Therapeutics Inc overvalued?
According to Wall Street analysts Protagonist Therapeutics Inc’s price is currently Undervalued.
Does Protagonist Therapeutics Inc pay dividends?
Protagonist Therapeutics Inc does not currently pay dividends.
What is Protagonist Therapeutics Inc’s EPS estimate?
Protagonist Therapeutics Inc’s EPS estimate is 2.43.
How many shares outstanding does Protagonist Therapeutics Inc have?
Protagonist Therapeutics Inc has 64,311,370 shares outstanding.
What happened to Protagonist Therapeutics Inc’s price movement after its last earnings report?
Protagonist Therapeutics Inc reported an EPS of $0.05 in its last earnings report, beating expectations of -$0.5. Following the earnings report the stock price went up 4.798%.
Which hedge fund is a major shareholder of Protagonist Therapeutics Inc?
Currently, no hedge funds are holding shares in PTGX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Protagonist Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$117.00 (10.40% Upside)
$117.00 (10.40% Upside)
Blogger Sentiment
Bullish
PTGX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 278.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $27.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.9%
Last 30 Days ▲ 4.3%
Last 30 Days ▲ 4.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
98.39%
12-Months-Change
Fundamentals
Return on Equity
-17.76%
Trailing 12-Months
Asset Growth
-6.02%
Trailing 12-Months
Company Description
Protagonist Therapeutics Inc
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
PTGX Stock 12 Month Forecast
Average Price Target
$117.00
▲(10.40% Upside)
Technical Analysis
ADMA Biologics
―
Zai Lab
―
―
Mirum Pharmaceuticals
―
Ascentage Pharma Group International Unsponsored ADR
―
Ownership Overview
1.19% Insiders
25.54% Mutual Funds
42.82% Other Institutional Investors
4.72% Public Companies and
Individual Investors